Temozolomide. A new option for high-grade astrocytomas.
Schwenka
J
J
University of California, San Francisco, California, USA.
Ignoffo
R J
RJ
D018906:Antineoplastic Agents, Alkylating / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D001855:Bone Marrow Diseases / Q000139:chemically induced; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D016527:Drug Costs; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D016019:Survival Analysis; D000077204:Temozolomide; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide